Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/307% below fair value
$32.86−0.55 (-1.63%)
Close on Nov 20, 2026Market cap $1.00BP/E –Yield 0.00%
Castle Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Castle Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was $3.96M, down 84.4% year over year. For fiscal 2025 it was $28.33M, down 22.5% from the year before. The highest annual figure on record is $36.54M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.33M | -22.5% |
| FY2024 | Dec 31, 2024 | $36.54M | – |
| FY2023 | Dec 31, 2023 | -$19.25M | – |
| FY2022 | Dec 31, 2022 | -$47.29M | – |
| FY2021 | Dec 31, 2021 | -$22.47M | -539.3% |
| FY2020 | Dec 31, 2020 | $5.11M | -15.9% |
| FY2019 | Dec 31, 2019 | $6.08M | – |
| FY2018 | Dec 31, 2018 | -$12.57M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.25M | +57.1% |
| Q2 FY2026 | Jun 30, 2026 | $6.55M | -43.3% |
| Q1 FY2026 | Mar 31, 2026 | -$34.58M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.75M | +17.6% |
| Q3 FY2025 | Sep 30, 2025 | $7.80M | -54.0% |
| Q2 FY2025 | Jun 30, 2025 | $11.56M | -38.4% |
| Q1 FY2025 | Mar 31, 2025 | -$10.78M | – |
| Q4 FY2024 | Dec 31, 2024 | $16.80M | +13.5% |
| Q3 FY2024 | Sep 30, 2024 | $16.96M | +563.3% |
| Q2 FY2024 | Jun 30, 2024 | $18.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.99M | – |
| Q4 FY2023 | Dec 31, 2023 | $14.79M | – |
| Q3 FY2023 | Sep 30, 2023 | $2.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.35M | -162.6% |
| Q1 FY2021 | Mar 31, 2021 | -$4.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.02M | -124.6% |
| Q3 FY2020 | Sep 30, 2020 | -$4.86M | -929.5% |
| Q2 FY2020 | Jun 30, 2020 | $11.75M | +3789.1% |
| Q1 FY2020 | Mar 31, 2020 | -$751.00K | -171.9% |
| Q4 FY2019 | Dec 31, 2019 | $4.15M | – |
| Q3 FY2019 | Sep 30, 2019 | $586.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $302.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $1.04M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.22M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.97M | – |
See a number that looks wrong?